Literature DB >> 1521517

Diagnosis and endocrine testing in acromegaly.

B M Chang-DeMoranville1, I M Jackson.   

Abstract

Acromegaly is a characteristic clinical syndrome resulting from excessive production of GH and SmC/IGF-I generally from a GH-producing pituitary tumor. Once the diagnosis is suspected on clinical grounds, it should be established based on persistent elevation of the basal GH, along with an increased SmC/IGF-I level; it is confirmed by a lack of suppressibility of GH levels following a glucose load. Other tests, including the paradoxic GH elevation in response to TRH and LHRH, are helpful in establishing the diagnosis, as well as determining and monitoring the outcome of surgical and medical therapy. The past few years have been enriched with new knowledge in the area of IGF-binding proteins. Evidence of clinical correlation exists regarding GH status, IGF-I levels, and the IGFBPs particularly IGFBP-1 and IGFBP-3. The value of IGFBPs in clinical practice as a diagnostic tool in disorders of GH secretion appears promising, but further studies are required.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521517

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

2.  Acromegaly in a cat: Diagnosis by magnetic resonance imaging and treatment by cryohypophysectomy.

Authors:  A C Abrams-Ogg; D L Holmberg; W A Stewart; F P Claffey
Journal:  Can Vet J       Date:  1993-11       Impact factor: 1.008

3.  Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.

Authors:  C Invitti; L Fatti; M G Camboni; L Porcu; L Danesi; G Delitala; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

4.  Retina ganglion cell/inner plexiform layer and peripapillary nerve fiber layer thickness in patients with acromegaly.

Authors:  Muhammed Şahin; Alparslan Şahin; Faruk Kılınç; Harun Yüksel; Zeynep Gürsel Özkurt; Fatih Mehmet Türkcü; Zafer Pekkolay; Hikmet Soylu; İhsan Çaça
Journal:  Int Ophthalmol       Date:  2016-08-04       Impact factor: 2.031

Review 5.  The evaluation and management of subclinical pituitary disease.

Authors:  S G Soule; H S Jacobs
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

6.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 7.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

8.  Improvement of acromegaly after octreotide LAR treatment.

Authors:  Ruth Mangupli; Aponte Lisette; Contreras Ivett; Camperos Paul; Cruz de los Ríos Victoria; Cevallos Jose Luis
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Visual field defects in 23 acromegalic patients.

Authors:  Emrah Kan; Elif Kilic Kan; Aysegul Atmaca; Hulusi Atmaca; Ramis Colak
Journal:  Int Ophthalmol       Date:  2013-02-09       Impact factor: 2.031

Review 10.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.